Qiang Li

Dr. Qiang Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
YWYu Wang
Yu Wang
MJMingyue Jin
Mingyue Jin
CCChak Kwong Cheng
Chak Kwong Cheng
QLQiang Li
Qiang Li
Diabetic kidney disease (DKD) is a chronic complication of diabetes and the leading cause of end-stage renal disease (ESRD) worldwide. Currently, there are limited therapeutic drugs available for DKD. While previous research has primarily focused on glomerular injury, recent studies have increasingly emphasized the role of renal tubular injury in the pathogenesis of DKD. Various factors, including hyperglycemia, lipid accumulation, oxidative stress, hypoxia, RAAS, ER stress, inflammation, EMT and programmed cell death, have been shown to induce renal tubular injury and contribute to the progression of DKD. Additionally, traditional hypoglycemic drugs, anti-inflammation therapies, anti-senescence therapies, mineralocorticoid receptor antagonists, and stem cell therapies have demonstrated their potential to alleviate renal tubular injury in DKD. This review will provide insights into the latest research on the mechanisms and treatments of renal tubular injury in DKD.

26 February 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
CXChang Xue
Chang Xue
TWTianying Wang
Tianying Wang
YCYang Chen
Yang Chen
HZHe Zhang
He Zhang
HWHongjie Wang
Hongjie Wang
QLQiang Li
Qiang Li
Background: The gut microbiota plays a pivotal role in various metabolic disorders. Orlistat has shown beneficial effects on weight loss and metabolism, but its direct impact on the gut microbiota has not been extensively reported. Thus, this study aimed to explore the effects of orlistat on the gut microbiota in mice with high-fat diet-induced obesity.Methods: Thirty male C57BL/6J mice were randomly divided into a normal control group (fed a standard diet, N), and a model group (fed a 60% fat diet). A body weight exceeding the basal body weight by 130% defined a successfully established obesity model. The model group was further divided into a positive control group (fed a 60% fat diet, F), and an orlistat group (fed a 60% fat diet and treated with orlistat at 30 mg/kg, bid, A), with 10 mice in each group. The parameters assessed included weight loss, fasting plasma glucose (FPG) levels, and intestinal hormones. Gut microbiota diversity was analyzed using high-throughput sequencing.Results: Orlistat treatment significantly reduced body weight and FPG levels, and increased glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) levels in obese mice. High-fat diet-fed mice exhibited increased microbial diversity and richness, which were significantly diminished by orlistat administration. Additionally, orlistat treatment led to a significant decrease in the proportion of Bacteroidetes and an increase in the proportion of Helicobacter and Allobaculum. Notable shifts in the abundances of Bacteroidetes were observed, correlating with changes in several functional metabolic pathways, including “cell motility” and “neurodegenerative diseases.” Co-occurrence network analysis suggested a more complex bacterial network in orlistat-treated mice, alongside a reduction in the density of bacterial correlation networks.Conclusions: Our study demonstrates that orlistat’s beneficial effects on body weight, FPG, GLP-1, and GIP are likely mediated through modifications in the gut microbiota composition.

26 October 2023 in Journal of Physiology and Biochemistry
Verified
Journal Article
Closed access
PDF file
PWPengfei Wei
Pengfei Wei
LLLixuan Li
Lixuan Li
CRChenqiu Ran
Chenqiu Ran
MJMingyue Jin
Mingyue Jin
HZHuijuan Zhao
Huijuan Zhao
JGJing Guo
Jing Guo

1 July 2025 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
YQYawei Qiu
Yawei Qiu
LGLin Guo
Lin Guo
HPHongyan Pan
Hongyan Pan
HHHuaqiu He
Huaqiu He
QLQiang Li
Qiang Li
There are few studies comparing Type 3 autoimmune polyendocrine syndromes (APS) with isolated type 1 diabetes mellitus (T1DM), latent autoimmune diabetes in youth (LADY), and latent autoimmune diabetes in adults (LADA) in the Chinese population. This study aims to report the clinical and serological characteristics of Chinese patients with Type 3 APS, isolated T1DM, LADY and LADA, and to make comparisons. This study retrospectively analyzed the clinical and serological characteristics of hospitalized patients with Type 3 APS, T1DM, LADY and LADA who were admitted to our center. A total of 69 patients were included in this study, comprising 18 with Type 3 APS, 20 with T1DM, and 31 with LADY/LADA. The majority of Type 3 APS patients were female, whereas T1DM and LADY/LADA groups had a higher proportion of males. The median age and onset age of diabetes in the Type 3 APS group were 35.50 (31.00, 52.50) years and 30.50 (26.75, 47.25) years, respectively. Diabetes and autoimmune thyroid disease (AITD) in Type 3 APS patients may occur simultaneously or several years apart. The levels of GADAb and thyroid autoantibodies in Type 3 APS patients were often higher. Type 3 APS exhibits differences when compared to isolated T1DM and LADY/LADA. For patients with TIDM or LADY/LADA, especially female patients, those over 30 years old or with high-titer GADAb, attention should be paid to screening for APS 3, including the detection of thyroid autoantibodies. Patients suspected or confirmed to have Type 3 APS need long-term follow-up. Not applicable.

9 July 2026 in European Heart Journal
Verified
Journal Article
Closed access
QCQiuyu Cao
Qiuyu Cao
XXXingkun Xu
Xingkun Xu
HLHong Lin
Hong Lin
YYYue Yin
Yue Yin
SWShengli Wu
Shengli Wu
JLJieli Lu
Jieli Lu
Traditional Cox proportional hazards models show suboptimal performance for cardiovascular disease (CVD) risk prediction in Chinese populations. Transformer-based deep learning models have demonstrated promise in clinical risk prediction. In this study, sex-specific transformer-based models (China-AIHeart) for 10-year CVD risk prediction among Chinese adults were developed and validated. The derivation cohort included 156 790 participants [34.6% men; mean [SD] age, 56.7 [8.9] years) without CVD from the China Cardiometabolic Disease and Cancer Cohort. External validation was conducted in two independent Chinese cohorts (Xinjiang and CHARLS). Transformer-based time-to-event prediction models were developed, including a full model (22 predictors) and a simplified model (15 predictors). Performance was compared with Cox models using identical predictors and established risk scores (China-PAR, PREVENT-ASCVD, and SCORE2 Asia-Pacific equations). China-AIHeart demonstrated good discrimination (C-statistic [95% confidence interval, CI]: .767 [.754-.779] in men; .780 [.769-.791] in women), calibration (calibration χ2: 14.806 in men; 9.326 in women; Brier score: .104 in men; .077 in women), and net clinical benefit in predicting CVD risk. Predicted event rates closely matched observed risks across strata. Compared with Cox models with identical predictors, China-AIHeart showed improved discrimination (ΔC-statistic [95% CI]: .027 [.025-.028] in men; .031 [.029-.033] in women) and reclassification (net reclassification index [95% CI]: .478 [.466-.492] in men; .560 [.551-.572] in women), and outperformed China-PAR, PREVENT-ASCVD, and SCORE2 Asia-Pacific equations. External validation demonstrated robust performance, with C-statistics of .781/.825 (men/women) and .748/.820 for the full and simplified models in the Xinjiang cohort, and .740/.771 for the simplified model in the CHARLS cohort. The transformer-based China-AIHeart models predicted 10-year CVD risk and outperformed traditional Cox-based approaches, providing a practical tool for risk stratification in Chinese adults.

31 October 2022 in Research Square
Verified
Preprint
Open access
PDF file
PWPengfei Wei
Pengfei Wei
LLLixuan Li
Lixuan Li
CRChenqiu Ran
Chenqiu Ran
MJMingyue Jin
Mingyue Jin
HZHuijuan Zhao
Huijuan Zhao
JGJing Guo
Jing Guo
The global prevalence and incidence of nonalcoholic fatty liver disease (NAFLD) exhibit a growing trend. Although its underlying mechanism is still unknown, NAFLD is characterized by a significant accumulation of lipids. Here we report that high-fat diet (HFD) feeding HFD induced hepatic steatosis in mice, accompanied by a reduction in the expression and function of hepatic TRPV2. By conditional knockout TRPV2 in hepatocytes, we found that HFD-induced hepatic steatosis was exacerbated. In vitro model of NAFLD, we found TRPV2 regulated the lipid accumulation in HepG2 cells, and TRPV2 activation inhibited the expression ofp21andp16which are cellular senescence markers. Finally, we found administration of probenecid, TRPV2 agonist, impaired HFD-induced hepatic steatosis and suppressed HFD-induced elevation inp21andp16. Collectively, our findings imply that hepatic TRPV2 protects against the accumulation of lipids by modulatingp21signaling.